Chestnut Hill, MA, United States, February 25th, 2026, FinanceWireLung Cancer Group has released a new overview analyzing ...

Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ ...

Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on ...

Although plastic particles in the air are increasingly coming into focus, knowledge about their distribution and effects is still limited. Chemical analyses from Leipzig now provide details from ...

Global Liquid Biopsy Market OverviewThe global liquid biopsy market is anticipated to register a strong compound annual growth rate of around 17% through 2031, driven by the increasing global burden ...

Q4 2025 Earnings Call March 2, 2026 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

Stage 1 mesothelioma is localized. The cancer is confined to one side of the chest lining or one area of the abdomen and has not spread to lymph nodes or distant organs. At this stage, treatment may ...

Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.

Keller’s goal is for Daichii-Sankyo’s portfolio of two approved ADCs to be up to four by 2030, with approvals for IDXD as well as raludotatug deruxtecan (RDXD). The idea is to extract as much value ...